DOCSLIB.ORG

Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and Its Newer RelaVes

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and Its Newer Rela�Ves 3/18/16 Successful Use of Repurposed Drugs for MDR TB: Meropenem/Clavulanate and its Newer Rela?ves Maunank Shah MD PhD Assistant Professor Center for TB Research & Center for Clinical Global Health Educaon Johns Hopkins University BalDmore City Health Department When opDons are limited… • 42 y/o from Peru with MDR-TB – Resistant to HRZE, ethionomide • AdmiSed with sepsis and ARDS • Not taking PO medicaons • LFTs in 1000’s, Tbili 12, Cr: 3.6 • REGIMEN: – IV Moxifloxacin, – IV Amikacin, – IV Linezolid – PAS, cycloserine not immediately available – What other drugs to add? 1 3/18/16 Learning ObjecDves • Understand the role of repurposed anDbioDcs and design stronger treatment regimens for paents with MDR and XDR TB • IdenDfy the toxiciDes associated with these medicaons and improve their ability to monitor and detect them • Discuss the strengths and limitaons of incorporang repurposed anDbioDcs into MDR/XDR TB treatment regimens and improve their ability to appropriately use these agents. Outline • Background: – What is a carbapenem? – How do carbapenems work? – What are carabapenems used for? • Carbapenems for the treatment of M. tuberculosis – In vitro data – In vivo data – Clinical data • Summary and outstanding quesDons 2 3/18/16 What is a carbapenem: core structure 1 6 5 2 7 4 3 • Part of the ‘penicillin’ family (Beta-Lactams) • Has extremely broad spectrum of acDvity: • Gram posiDves, Gram negaves and anaerobes • Tends to be acDve even in presence of bacterial “beta-lactamases” Carbapenems: last line of defense • Currently at least 2million illnesses and 23,000 deaths in the US from drug-resistant bacteria – Carbapenems oAen the only drug class with retained sensi?vity – Carbapenems are the drug of choice for ESBL (extended spectrum beta lactamase) producing organisms • Carbapenems also have acvity against mycobacteria hSp://www.cdc.gov/drugresistance/biggest_threats.html 3 3/18/16 How do they work: Carbapenems aack the cell wall of bacteria • The pepdoglycan layer is present in virtually all bacteria. • This layer is essenDal for survival and growth of bacteria. pepDdoglycan Paul & Beveridge: Infect. Immun. 1994. p.1542 M. tuberculosis SEM. JHU EM Core Facility, 2001. Hayhurst et al, PNAS, 2008 How do Carbapenems work against M. tuberculosis Carbapenems can block the 3-3 linkage β-lactam drugs In M. tuberculosis L-Ala D-Ala 4 D-Glu D-Ala 3 3 mDap mDap 3 PepDdoglycan TranspepDdase D-Glu D-Ala layer L-Ala MTB TranspepDdase Membrane Cytosol 4 3/18/16 Carbapenems are not readily impacted by the β-lactamase produced by M. tuberculosis Carbapenem BlaC Beta- BlaC Beta- lactamase lactamase Clavulanic acid M. tuberculosis M. tuberculosis penicillin BlaC Beta- lactamase Hugonnet et al. Science. 2009 Carbapenems covalently bind and inhibit β-lactamase • Meropenem inhibits BlaC in a dose dependent manner • Also seen with doripenem, ertapenem and tebipenem Hugonnet. Science 2009; Tremblay Biochemistry 2010; Hazra Biochemistry 2014 5 Figure S1. Slow-onset inhibition of BlaC with meropenem. (A) Time courses of nitrocefin hydrolysis with increasing concentration of meropenem (top panel). (B) Rate of isomerization (kiso) versus concentration of meropenem (lower panel). 3/18/16 B-Lactamase Inhibitors also bind to BlaC • Clavulanate, Sulbactam, Tazobactam Hugonnet• andClavulanate Blanchard is the only one that irreversibly inhibited PageBlaC 11 TAZOBACTAM NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript SULBACTAM CLAVULANATE Figure 4. Recovery of BlaC activity after incubation with β-lactamase Hugonnetinhibitors Biochemistry 2007 Enzyme (20 μM) was incubated with 100 μM sulbactam (▲), 100 μM tazobactam (■) or 100 μM clavulanate (●), and activity was determined at the indicated times. Currently Carbapenems are listed as Group 5 drugs for the treatment of MDR-TB Step 1: Include any first-line Step 3: Include an drugs to which the isolate is Step 2: Add a fluoroquinolone injectable agent susceptible Fluoroquinolone First-line Drugs Injectables Levofloxacin Kanamycin Ethambutol Moxifloxacin Amikacin Pyrazinamide Gatifloxacin Capreomycin High-dose isoniazid Streptomycin Oral Group 4 Drugs Group 5 Drugs Step 4: Include second-line Ethionamide drugs until you have 4-6 Clofazimine Prothionamide drugs to which the isolate is Clarithromycin Cycloserine/Terizidone susceptible Amoxicillin-clavulanate Para-aminosalicylic acid Consider third-line drugs if Linezolid there are not 4-6 drugs to Thiacetazone which the isolate is Meropenem-clavulanate susceptible Thioridazine Adapted from: Curry International Tuberculosis Center. Drug-resistant tuberculosis: a survival guide for clinicians. Chang KC, et al. Respirology. 2013;18:8-21. 6 Biochemistry. Author manuscript; available in PMC 2008 December 4. 3/18/16 Evidence for using Carbapenems for MTB: Is it Dme to move on from “Group 5”? • In Vitro data • In Vivo data (i.e. animal models) • Clinical data In Vitro Data 7 REPORTS The combination of clavulanate with b- culosis. Thirteen clinical isolates exhibiting the were determined. The susceptibility of these strains lactams, especially meropenem, was also tested XDR phenotype were tested (18). Clavulanate was experimentally indistinguishable from that Kumarfor the et abilityal. to inhibit the growth of extensively was used at a concentration of 2.5 mgml–1,and determinedPage 18 for H37Rv and the Erdman strain, drug-resistant (XDR) clinical strains of M. tuber- the MIC values of these strains for meropenem that is, ≤1 mgml–1 (Table 1). In contrast, sub- 3/18/16 stantial variability in the MIC values to ampicil- lin, amoxicillin, cephalothin, and imipenem was NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author Manuscript observed for these same strains (table S2). The clavulanate-meropenem combination is thus equal- ly effective against both susceptible and XDR strains. These structural and mechanistic studies of carbapenem interactions with the BlaC b-lactamase ASacking the Cell Wall have revealed properties of specific b-lactam an- tibiotics that can be exploited in the treatment of Altered morphology tuberculosis, including the treatment of multidrug- and extensively drug-resistant strains. The struc- ture of the meropenem-inactivated acyl-enzyme, in combination with our mechanistic proposal for its hydrolysis and the structure of the clavulanate- BlaC complex, provides the information neces- sary to design improved tuberculosis-specific b-lactams that could form longer-lived acyl-enzyme intermediates. Among currently approved b- lactams, however, meropenem is superior on the basis of its poor activity as a substrate for BlaC, ability to transiently inhibit BlaC, and activity against nonreplicating organisms. This activity provides experimental evidence that peptidoglycan CONTROL 1X MIC90 - 10X 1X MIC90 - remodeling occurs in M. tuberculosis in the non- Fig. 2. replicating state, which may be an important SEM images showing effectsMEROCLAV of meropenem exposureMEROCLAV on Mtb cell shape. (A & B)determinant untreated of clinical efficacy. In culture, meropenem+clavulanic acid controls, (C & D) treated with 1X MCA, (E & F) with 10X MCA or (G & H) with 10XTen yearsINH ago, a report on the early bacteri- Leads to cidal (i.e.lyc killing) acDvity against MTB (Bar=1 μm). The lower magnification pictures shown above (A, C, E, G) were capturedcidal activity at of amoxicillin-clavulanate in pa- 8,000 X and corresponding higher magnification pictures shown below (B, D, F, I) were Kumar, Mol Microbio 2012 tients with tuberculosis appeared (19), but no captured at 25, 000 X. additional reports have appeared since then. Our studies reveal that clinical strain-to-strain varia- bility is observed with combinations of clavulanate with penicillins, cephalosporins, and imipenem Fig. 2. (A) Overall structure of BlaC displayed in rainbow from N term (blue) to the C term (red), but not with meropenem. The synergism of the with the meropenem adduct displayed as a surface mesh. (B) Fo–Fc omit density (green) contoured clavulanate-meropenem combination and the at 4.0 s surrounds the covalent meropenem adduct formed at the Ambler active-site residue Ser70. uniform activity against drug-susceptible, labo- Mero/ClavStructure has acDvity on Replicang Bacteria figures were produced using Pymol (www.pymol.org). (C) Proposed chemical mechanism ratory, and XDR clinical strains suggest this for the BlaC-catalyzed reactionin vitro with meropenem. combination could be useful in the treatment of –1 Fig.Killing curves of MTB in aerobic growth aer exposure 3. Killing curves of M. tuberculosis after exposure to b-lactams and meropenem (0.19 to 12.5 mg ml ) in the presence or absence of 2.5 mg clavulanate. (A) Aerobic growth using the microdilution method. Merope- ml–1 clavulanate. Isoniazid (0.16 to 1.0 mgml–1)andmetronidazole(4.6to73 nemto Meropenem and clavulanate were/Clav added at 5 different concentraons at 2 mg ml–1 +1mgml–1 (■), 2 mg ml–1 + mM) served as negative and positive controls, respectively. Survival was 2 mg ml–1 (□), 4 mgmlMol–1 +1Microbiolmg ml. Author–1 (▲), manuscript; and 4 mgml available–1 +2 inm PMCg ml –20131 (D ),Octoberdetermined 01. by measurement of ATP amounts in surviving bacteria during Hugonnet. Science 2009 respectively, for 5 consecutive days. (B) Meropenem is cidal for non- aerobic outgrowth of 100-fold diluted cells at either 1 week (white bars) or 2 replicating anaerobic M. tuberculosis. Hypoxically adapted M. tuberculosis weeks (shaded bars) of treatment or by enumeration of CFUs (inset) after 2 H37Rv was treated under anaerobic conditions with twofold dilutions of weeks of compound exposure. www.sciencemag.org SCIENCE VOL 323 27 FEBRUARY 2009 1217 8 3/18/16 AcDvity of Carbapenems against M. tuberculosis and XDR-TB strains One representa?ve study NOTE: Wide range of MICs in other studies --methodologic study differences (in defining MIC) MIC range in this study: 0.23-1.25 Hugonnet et al. Science. 2009 AddiDon of B-Lactamase reduces MIC Higher MICs found in this study Differences in MICs Drop in half of MIC with AddiDon of clavulanic acid Newer carbapenems appear To have lower MICs (and some are oral!) Kaushik et al, AAC, 2015. 9 Zhang et al.
Load more

Recommended publications
  • Polymyxin B in Combination with Doripenem Against Heteroresistant Acinetobacter Baumannii: Pharmacodynamics of New Dosing Strategies
    J Antimicrob Chemother 2016; 71: 3148–3156 doi:10.1093/jac/dkw293 Advance Access publication 3 August 2016 Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies Gauri G. Rao1,2, Neang S. Ly1,2,Ju¨rgen B. Bulitta1,3, Rachel L. Soon1,2, Marie D. San Roman1,2, Patricia N. Holden1,2, Cornelia B. Landersdorfer4, Roger L. Nation4, Jian Li4, Alan Forrest1,5 and Brian T. Tsuji1,2* 1Laboratory for Antimicrobial Pharmacodynamics, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA; 2The New York State Center of Excellence in Bioinformatics & Life Sciences, University at Buffalo, The State University of New York, Buffalo, NY, USA; 3Center for Pharmacometrics and Systems Pharmacology, College of Pharmacy, University of Florida, Orlando, FL, USA; 4Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Australia; 5Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, NC, USA *Corresponding author. Tel: +1-716-881-7543; Fax: +1-716-849-6890; E-mail: [email protected] Received 13 October 2015; returned 3 January 2016; revised 14 June 2016; accepted 19 June 2016 Objectives: Polymyxin B is being increasingly utilized as a last resort against resistant Gram-negative bacteria. We examined the pharmacodynamics of novel dosing strategies for polymyxin B combinations to maximize efficacy and minimize the emergence of resistance and drug exposure against Acinetobacter baumannii. Methods: The pharmacodynamics of polymyxin B together with doripenem were evaluated in time–kill experi- ments over 48 h against 108 cfu/mL of two polymyxin-heteroresistant A.
    [Show full text]
  • Medical Review(S) Clinical Review
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 200327 MEDICAL REVIEW(S) CLINICAL REVIEW Application Type NDA Application Number(s) 200327 Priority or Standard Standard Submit Date(s) December 29, 2009 Received Date(s) December 30, 2009 PDUFA Goal Date October 30, 2010 Division / Office Division of Anti-Infective and Ophthalmology Products Office of Antimicrobial Products Reviewer Name(s) Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD Review Completion October 29, 2010 Date Established Name Ceftaroline fosamil for injection (Proposed) Trade Name Teflaro Therapeutic Class Cephalosporin; ß-lactams Applicant Cerexa, Inc. Forest Laboratories, Inc. Formulation(s) 400 mg/vial and 600 mg/vial Intravenous Dosing Regimen 600 mg every 12 hours by IV infusion Indication(s) Acute Bacterial Skin and Skin Structure Infection (ABSSSI); Community-acquired Bacterial Pneumonia (CABP) Intended Population(s) Adults ≥ 18 years of age Template Version: March 6, 2009 Reference ID: 2857265 Clinical Review Ariel Ramirez Porcalla, MD, MPH Neil Rellosa, MD NDA 200327: Teflaro (ceftaroline fosamil) Table of Contents 1 RECOMMENDATIONS/RISK BENEFIT ASSESSMENT ......................................... 9 1.1 Recommendation on Regulatory Action ........................................................... 10 1.2 Risk Benefit Assessment.................................................................................. 10 1.3 Recommendations for Postmarketing Risk Evaluation and Mitigation Strategies ........................................................................................................................
    [Show full text]
  • Pharmacodynamic Evaluation of Suppression of in Vitro Resistance In
    www.nature.com/scientificreports OPEN Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B‑based combination therapy Nayara Helisandra Fedrigo1, Danielle Rosani Shinohara1, Josmar Mazucheli2, Sheila Alexandra Belini Nishiyama1, Floristher Elaine Carrara‑Marroni3, Frederico Severino Martins4, Peijuan Zhu5, Mingming Yu6, Sherwin Kenneth B. Sy2 & Maria Cristina Bronharo Tognim1* The emergence of polymyxin resistance in Gram‑negative bacteria infections has motivated the use of combination therapy. This study determined the mutant selection window (MSW) of polymyxin B alone and in combination with meropenem and fosfomycin against A. baumannii strains belonging to clonal lineages I and III. To evaluate the inhibition of in vitro drug resistance, we investigate the MSW‑derived pharmacodynamic indices associated with resistance to polymyxin B administrated regimens as monotherapy and combination therapy, such as the percentage of each dosage interval that free plasma concentration was within the MSW (%TMSW) and the percentage of each dosage interval that free plasma concentration exceeded the mutant prevention concentration (%T>MPC). The MSW of polymyxin B varied between 1 and 16 µg/mL for polymyxin B‑susceptible strains. The triple combination of polymyxin B with meropenem and fosfomycin inhibited the polymyxin B‑resistant subpopulation in meropenem‑resistant isolates and polymyxin B plus meropenem as a double combination sufciently inhibited meropenem‑intermediate, and susceptible strains. T>MPC 90% was reached for polymyxin B in these combinations, while %TMSW was 0 against all strains. TMSW for meropenem and fosfomycin were also reduced. Efective antimicrobial combinations signifcantly reduced MSW. The MSW‑derived pharmacodynamic indices can be used for the selection of efective combination regimen to combat the polymyxin B‑resistant strain.
    [Show full text]
  • Ladenburg Thalmann Healthcare Conference
    Ladenburg Thalmann Healthcare Conference July 13, 2021 Forward-looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, the design, initiation, timing and submission to the U.S. Food and Drug Administration (FDA) of a New Drug Application (NDA) for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift in treating patients from intravenous to oral administration; the initiation, timing, progress and results of the Company’s preclinical studies and clinical trials and its research and development programs, including management’s assessment of such results; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on the Company’s business and operations; the timing of the availability of data from the Company’s clinical trials; the timing of the Company’s filings with regulatory agencies; product candidate benefits; competitive position; business strategies; objectives of management; potential growth opportunities; potential market size; reimbursement matters; possible or assumed future results of operations; projected costs; and the Company’s cash forecast and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions.
    [Show full text]
  • United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith Et Al
    US010561675B2 United States Patent ( 10 ) Patent No.: US 10,561,6759 B2 Griffith et al. (45 ) Date of Patent : * Feb . 18 , 2020 (54 ) CYCLIC BORONIC ACID ESTER ( 58 ) Field of Classification Search DERIVATIVES AND THERAPEUTIC USES CPC A61K 31/69 ; A61K 31/396 ; A61K 31/40 ; THEREOF A61K 31/419677 (71 ) Applicant: Rempex Pharmaceuticals , Inc. , (Continued ) Lincolnshire , IL (US ) (56 ) References Cited (72 ) Inventors : David C. Griffith , San Marcos, CA (US ) ; Michael N. Dudley , San Diego , U.S. PATENT DOCUMENTS CA (US ) ; Olga Rodny , Mill Valley , CA 4,194,047 A 3/1980 Christensen et al . ( US ) 4,260,543 A 4/1981 Miller ( 73 ) Assignee : REMPEX PHARMACEUTICALS , ( Continued ) INC . , Lincolnshire , IL (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer, the term of this EP 1550657 A1 7/2005 patent is extended or adjusted under 35 JP 2003-229277 A 8/2003 U.S.C. 154 ( b ) by 1129 days. (Continued ) This patent is subject to a terminal dis claimer . OTHER PUBLICATIONS Abdel -Magid et al. , “ Reductive Amination ofAldehydes and Ketones ( 21) Appl. No .: 13 /843,579 with Sodium Triacetoxyborohydride: Studies on Direct and Indirect Reductive Amination Procedures ” , J Org Chem . ( 1996 )61 ( 11 ): 3849 ( 22 ) Filed : Mar. 15 , 2013 3862 . (65 ) Prior Publication Data (Continued ) US 2013/0331355 A1 Dec. 12 , 2013 Primary Examiner — Shengjun Wang Related U.S. Application Data (74 ) Attorney, Agent, or Firm — Wilmer Cutler Pickering (60 ) Provisional application No.61 / 656,452 , filed on Jun . Hale and Dorr LLP 6 , 2012 (57 ) ABSTRACT (51 ) Int. Ci. A61K 31/69 ( 2006.01) Method of treating or ameliorating a bacterial infection A61K 31/00 ( 2006.01 ) comprising administering a composition comprising a cyclic (Continued ) boronic acid ester compound in combination with a car ( 52 ) U.S.
    [Show full text]
  • General Items
    Essential Medicines List (EML) 2019 Application for the inclusion of imipenem/cilastatin, meropenem and amoxicillin/clavulanic acid in the WHO Model List of Essential Medicines, as reserve second-line drugs for the treatment of multidrug-resistant tuberculosis (complementary lists of anti-tuberculosis drugs for use in adults and children) General items 1. Summary statement of the proposal for inclusion, change or deletion This application concerns the updating of the forthcoming WHO Model List of Essential Medicines (EML) and WHO Model List of Essential Medicines for Children (EMLc) to include the following medicines: 1) Imipenem/cilastatin (Imp-Cln) to the main list but NOT the children’s list (it is already mentioned on both lists as an option in section 6.2.1 Beta Lactam medicines) 2) Meropenem (Mpm) to both the main and the children’s lists (it is already on the list as treatment for meningitis in section 6.2.1 Beta Lactam medicines) 3) Clavulanic acid to both the main and the children’s lists (it is already listed as amoxicillin/clavulanic acid (Amx-Clv), the only commercially available preparation of clavulanic acid, in section 6.2.1 Beta Lactam medicines) This application makes reference to amendments recommended in particular to section 6.2.4 Antituberculosis medicines in the latest editions of both the main EML (20th list) and the EMLc (6th list) released in 2017 (1),(2). On the basis of the most recent Guideline Development Group advising WHO on the revision of its guidelines for the treatment of multidrug- or rifampicin-resistant (MDR/RR-TB)(3), the applicant considers that the three agents concerned be viewed as essential medicines for these forms of TB in countries.
    [Show full text]
  • AMR Surveillance in Pharma: a Case-Study for Data Sharingauthor by Professor Barry Cookson
    AMR Open Data Initiative AMR Surveillance in Pharma: a case-study for data sharingauthor by Professor Barry Cookson External Consultant to Project eLibrary • Division of Infection and Immunity, Univ. College London ESCMID• Dept. of Microbiology, © St Thomas’ Hospital Background of “90 day Project” Addressed some recommendations of the first Wellcome funded multi-disciplinary workshop (included Pharma Academia & Public Health invitees: 27thauthor July 2017 (post the Davos Declaration): by 1) Review the landscape of existing Pharma AMR programmes, their protocols,eLibrary data standards and sets 2) Develop a "portal" (register/platform) to access currently available AMR Surveillance data ESCMID Important ©to emphasise that this is a COLLABORATION between Pharma and others Overview of Questionnaire Content • General information - including name,author years active, countries, antimicrobials, microorganisms.by • Methodology - including accreditation, methodology for; surveillance, isolate collection, organism identification, breakpointseLibrary used, • Dataset - including data storage methodology, management and how accessed. ESCMID © 13 Company Responses author 7 by 3 3 eLibrary ESCMID © Structure of register Companies can have different ways of referring to their activities: We had to choose a consistent framework. author Companies Companyby 1 Programmes Programme A Programme B eLibrary Antimicrobials 1 2 3 4 5 company’s product comparator company’s product antimicrobials Programmes canESCMID contain multiple studies (e.g. Pfizer has© single
    [Show full text]
  • Penicillin Skin Testing
    Penicillin Skin Testing Penicillin Skin Testing: Frequently Asked Questions Benzylpenicilloyl Polylysine (Pre-Pen®) and Diluted Penicillin G June 2012 VA Pharmacy Benefits Management Services, Medical Advisory Panel and VISN Pharmacist Executives Benzylpenicilloyl polylysine (Pre-Pen®) was FDA approved in 2009 for the assessment of sensitization to penicillin in those patients suspected, based upon previous experience, of having a clinical hypersensitivity to penicillin. Penicillin skin testing is the most reliable way to evaluate patients for IgE-mediated penicillin allergy. Skin testing is conducted using benzylpenicilloyl polylysine (major determinant), penicillin G diluted with normal saline to 10,000 units/ml (minor determinant), a positive and negative control. Testing with both the major and minor determinant of penicillin can identify up to 97% of patients with an immediate hypersensitivity to penicillin. The intent of this document is to help guide appropriate use of penicillin skin testing. 1. WHEN IS PENICILLIN SKIN TESTING INDICATED? Penicillin skin testing can be considered in those patients with a prior history of hypersensitivity to penicillin or allergy to penicillin in situations where the provider considers penicillin the drug of choice or prefers treatment with penicillin. If skin testing is indicated, the patient should be referred to a VA Allergy Specialist or other appropriately trained physician who is experienced in the application and interpretation of PCN skin testing, as locally designated. Although approximately 10% of patients will remain allergic to penicillin their entire lives, a large majority will stop expressing penicillin-specific IgE-mediated antibodies and can be safely treated with penicillin. Skin testing with benzylpenicilloyl polylysine is contraindicated in patients who are known to be extremely hypersensitive to penicillin and in those patients who have experienced a systemic or marked local reaction to prior administration of benzylpenicilloyl polylysine.
    [Show full text]
  • Spero Therapeutics to Present Data for All Pipeline Programs at Idweek 2020
    Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 October 16, 2020 15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial CAMBRIDGE, Mass., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will have 15 data presentations at the Infectious Disease Society of America (IDSA) IDWeek™ 2020 taking place virtually from October 21 - 25, 2020. Presentations will cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial that evaluated Spero’s oral antibiotic investigational candidate, tebipenem HBr, for the treatment of adults with complicated urinary tract infection (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line data from the trial demonstrating that oral tebipenem HBr was statistically non-inferior to intravenous (IV) ertapenem in the treatment of patients with cUTI and patients with AP. Poster presentations include a poster on the Phase 1 clinical trial of SPR720, an oral antimicrobial investigational agent in clinical development by Spero for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. In December 2019, Spero announced
    [Show full text]
  • In Vitro Susceptibilities of Escherichia Coli and Klebsiella Spp. To
    Jpn. J. Infect. Dis., 60, 227-229, 2007 Short Communication In Vitro Susceptibilities of Escherichia coli and Klebsiella Spp. to Ampicillin-Sulbactam and Amoxicillin-Clavulanic Acid Birgul Kacmaz* and Nedim Sultan1 Department of Central Microbiology and 1Department of Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkey (Received January 30, 2007. Accepted April 13, 2007) SUMMARY: Ampicillin-sulbactam (A/S) and amoxicillin-clavulanic acid (AUG) are thought to be equally efficacious clinically against the Enterobacteriaceae family. In this study, the in vitro activities of the A/S and AUG were evaluated and compared against Escherichia coli and Klebsiella spp. Antimicrobial susceptibility tests were performed by standard agar dilution and disc diffusion techniques according to the Clinical and Laboratory Standards Institute (CLSI). During the study period, 973 strains were isolated. Of the 973 bacteria isolated, 823 were E. coli and 150 Klebsiella spp. More organisms were found to be susceptible to AUG than A/S, regardless of the susceptibility testing methodology. The agar dilution results of the isolates that were found to be sensitive or resistant were also compatible with the disc diffusion results. However, some differences were seen in the agar dilution results of some isolates that were found to be intermediately resistant with disc diffusion. In E. coli isolates, 17 of the 76 AUG intermediately resistant isolates (by disc diffusion), and 17 of the 63 A/S intermediately resistant isolates (by disc diffusion) showed different resistant patterns by agar dilution. When the CLSI breakpoint criteria are applied it should be considered that AUG and A/S sensitivity in E. coli and Klebsiella spp.
    [Show full text]
  • Below Are the CLSI Breakpoints for Selected Bacteria. Please Use Your Clinical Judgement When Assessing Breakpoints
    Below are the CLSI breakpoints for selected bacteria. Please use your clinical judgement when assessing breakpoints. The lowest number does NOT equal most potent antimicrobial. Contact Antimicrobial Stewardship for drug selection and dosing questions. Table 1: 2014 MIC Interpretive Standards for Enterobacteriaceae (includes E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia and Proteus spp) Antimicrobial Agent MIC Interpretive Criteria (g/mL) Enterobacteriaceae S I R Ampicillin ≤ 8 16 ≥ 32 Ampicillin-sulbactam ≤ 8/4 16/8 ≥ 32/16 Aztreonam ≤ 4 8 ≥ 16 Cefazolin (blood) ≤ 2 4 ≥ 8 Cefazolin** (uncomplicated UTI only) ≤ 16 ≥ 32 Cefepime* ≤ 2 4-8* ≥ 16 Cefotetan ≤ 16 32 ≥ 64 Ceftaroline ≤ 0.5 1 ≥ 2 Ceftazidime ≤ 4 8 ≥ 16 Ceftriaxone ≤ 1 2 ≥ 4 Cefpodoxime ≤ 2 4 ≥ 8 Ciprofloxacin ≤ 1 2 ≥ 4 Ertapenem ≤ 0.5 1 ≥ 2 Fosfomycin ≤ 64 128 ≥256 Gentamicin ≤ 4 8 ≥ 16 Imipenem ≤ 1 2 ≥ 4 Levofloxacin ≤ 2 4 ≥ 8 Meropenem ≤ 1 2 ≥ 4 Piperacillin-tazobactam ≤ 16/4 32/4 – 64/4 ≥ 128/4 Trimethoprim-sulfamethoxazole ≤ 2/38 --- ≥ 4/76 *Susceptibile dose-dependent – see chart below **Cefazolin can predict results for cefaclor, cefdinir, cefpodoxime, cefprozil, cefuroxime axetil, cephalexin and loracarbef for uncomplicated UTIs due to E.coli, K.pneumoniae, and P.mirabilis. Cefpodoxime, cefinidir, and cefuroxime axetil may be tested individually because some isolated may be susceptible to these agents while testing resistant to cefazolin. Cefepime dosing for Enterobacteriaceae ( E.coli, Klebsiella, Enterobacter, Citrobacter, Serratia & Proteus spp) Susceptible Susceptible –dose-dependent (SDD) Resistant MIC </= 2 4 8 >/= 16 Based on dose of: 1g q12h 1g every 8h or 2g every 8 h Do not give 2g q12 Total dose 2g 3-4g 6g NA Table 2: 2014 MIC Interpretive Standards for Pseudomonas aeruginosa and Acinetobacter spp.
    [Show full text]
  • New Β-Lactamase Inhibitor Combinations: Options for Treatment; Challenges for Testing
    MEDICAL/SCIENTIFIC AffAIRS BULLETIN New β-lactamase Inhibitor Combinations: Options for Treatment; Challenges for Testing Background The β-lactam class of antimicrobial agents has played a crucial role in the treatment of infectious diseases since the discovery of penicillin, but β–lactamases (enzymes produced by the bacteria that can hydrolyze the β-lactam core of the antibiotic) have provided an ever expanding threat to their successful use. Over a thousand β-lactamases have been described. They can be divided into classes based on their molecular structure (Classes A, B, C and D) or their function (e.g., penicillinase, oxacillinase, extended-spectrum activity, or carbapenemase activity).1 While the first approach to addressing the problem ofβ -lactamases was to develop β-lactamase stable β-lactam antibiotics, such as extended-spectrum cephalosporins, another strategy that has emerged is to combine existing β-lactam antibiotics with β-lactamase inhibitors. Key β-lactam/β-lactamase inhibitor combinations that have been used widely for over a decade include amoxicillin/clavulanic acid, ampicillin/sulbactam, and pipercillin/tazobactam. The continued use of β-lactams has been threatened by the emergence and spread of extended-spectrum β-lactamases (ESBLs) and more recently by carbapenemases. The global spread of carbapenemase-producing organisms (CPOs) including Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter baumannii, limits the use of all β-lactam agents, including extended-spectrum cephalosporins (e.g., cefotaxime, ceftriaxone, and ceftazidime) and the carbapenems (doripenem, ertapenem, imipenem, and meropenem). This has led to international concern and calls to action, including encouraging the development of new antimicrobial agents, enhancing infection prevention, and strengthening surveillance systems.
    [Show full text]